{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:56:48Z","timestamp":1792083408096,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In order to describe relapsed B\u2010cell non\u2010Hodgkin lymphoma and mature acute leukemia in children\/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the rituximab era, relapses in the French LMB2001 study were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B\u2010cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median time to relapse after diagnosis was 4.5 months (range 2.4\u201013.6). Thirty\u2010two patients received salvage therapy. Twenty\u2010seven received rituximab mainly in addition to high\u2010dose cytarabine and etoposide (n\u00a0=\u00a018) and\/or ifosfamide, carboplatin, and etoposide (n\u00a0=\u00a07). First\u2010line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty\u2010one patients received high\u2010dose chemotherapy (HDC) followed by autologous (n\u00a0=\u00a013) or allogeneic (n\u00a0=\u00a08) transplant. With a median follow\u2010up of 6.8 years, the 5\u2010year survival rate after relapse was 36.4% (95% confidence interval [CI] 22\u201053%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5\u2010year survival rate of 75% (95% CI 46.8\u201091.1%) for patients in CR before HDC, 33% (95% CI 9.7\u201070%) for patients in partial remission, and 0% for nonresponders (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.033).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Survival of children\/adolescents with mature B\u2010cell lymphoma\/leukemia remains poor after relapse with no apparent improvement with rituximab. Response rates to salvage chemo\u2010immunotherapies are insufficient and new drugs are urgently needed to improve disease control.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.27873","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T16:06:27Z","timestamp":1560787587000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Outcome of relapse in children and adolescents with B\u2010cell non\u2010Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-778X","authenticated-orcid":false,"given":"Charlotte","family":"Rigaud","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Auperin","sequence":"additional","affiliation":[{"name":"Department of Statistics Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jourdain","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Haouy","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Laure","family":"Couec","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-4460","authenticated-orcid":false,"given":"Nathalie","family":"Aladjidi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lambliotte","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology Centre Oscar Lambret  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Plat","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-1895","authenticated-orcid":false,"given":"Judith","family":"Landman\u2010Parker","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology Hospital Armand Trousseau  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Michon","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Institut Curie  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology Hospital Robert Debr\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-5207","authenticated-orcid":false,"given":"Veronique","family":"Minard\u2010Colin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology Gustave Roussy Cancer Campus  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.661"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1219"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"issue":"15","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized intergroup trial Inter\u2010B\u2010NHL Ritux 2010 for children and adolescents with high\u2010risk B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) and mature acute leukemia (B\u2010AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen","volume":"34","author":"Minard\u2010Colin V","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.121434"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02647.x"},{"issue":"8","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood.V90.8.2921","article-title":"High\u2010dose chemotherapy with autologous bone marrow rescue in children with poor\u2010risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry","volume":"90","author":"Ladenstein R","year":"1997","journal-title":"Blood"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21585"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.677534"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.047"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2390"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20121"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532402320219763"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04925.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15491"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681130"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010390203125"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26105"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj995"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"issue":"8","key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.V81.8.2003.2003","article-title":"Curability of relapsed childhood B\u2010cell non\u2010Hodgkin's lymphoma after intensive first line therapy: a report from the Soci\u00e9t\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique","volume":"81","author":"Philip T","year":"1993","journal-title":"Blood"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0338-4535(85)80026-X"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.9.979"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1804"},{"issue":"6","key":"e_1_2_9_32_1","first-page":"465","article-title":"High\u2010dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non\u2010Hodgkin's lymphoma","volume":"8","author":"Loiseau HA","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290017051"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.07.002"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.27873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:07:20Z","timestamp":1694315240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/pbc.27873"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27873","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"2018-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e27873"}}